최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한유전성대사질환학회지 = Journal of the Korean Society of Inherited Metabolic Disease, v.20 no.2, 2020년, pp.55 - 62
양성민 (연세대학교 원주의과대학 소아청소년과) , 최효원 (연세대학교 원주의과대학 소아청소년과) , 강윤구 (연세대학교 원주의과대학 소아청소년과) , 이진성 (연세대학교 의과대학 소아청소년과) , 남궁미경 (연세대학교 원주의과대학 소아청소년과)
A 22-month-old girl who had taken iron supplements due to iron deficiency anemia, presented bloody mucoid stool for one month. She had a bruise at the right periorbital area due to minor trauma and hepatosplenomegaly. Laboratory studies showed anemia, thrombocytopenia, elevated alkaline phosphatase ...
Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med 2017;19.
Pohorecka M, Biernacka M, Jakubowska-Winecka A, Biernacki M, Kusmierska K, Kowalik A, et al. Behavioral and intellectual functioning in patients with tyrosinemia type I. Pediatr Endocrinol Diabetes Metab 2012;18:96-100.
van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187-91.
Hahn SH, Pai KS, Lee KB, Park KH, Kim OH, Hong CH, et al. Acute Tyrosinemia Type 1 in a 5 Month Old Korean Boy. J Korean Pediatr Soc 1996;39:866-72.
Kim KT, Kim YM, Park SE, Nam SO, Park JH. Two Cases of Acute Form of Tyrosinemia Type I. J Korean Pediatr Soc 2002;45:131-6.
Cho JH, Shim KJ, Kim SK, Shin SH, Lee KH, Yun HS. A Case of Tyrosinemia Type 1 with Cytomegalovirus Infection. Clin Exp Pediatr 2004;47:111-4.
Park HD, Lee DH, Choi TY, Lee YK, Kim JW, Ki CS, et al. Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1. Clin Chem Lab Med 2009;47:930-3.
Choi HJ, Bang HI, Ki CS, Lee SY, Kim JW, Song J, et al. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I. Ann Clin Lab Sci 2014;44:317-23.
Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM. Different Clinical Forms of Hereditary Tyrosinemia (Type I) in Patients with Identical Genotypes. Molecular Genetics and Metabolism 1998;64:119-25.
Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. The Journal of Pediatrics 1976;88:434-8.
Ozcan HN, Karcaaltincaba M, Pektas E, Sivri HS, Oguz B, Dursun A, et al. Imaging liver nodules in tyrosinemia type-1: A retrospective review of 16 cases in a tertiary pediatric hospital. European Journal of Radiology 2019;116:41-6.
Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322:432-7.
Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31:81-7.
Couce ML, Sanchez-Pintos P, Aldamiz-Echevarria L, Vitoria I, Navas V, Martin-Hernandez E, et al. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain. Medicine (Baltimore) 2019;98:e17303.
van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs 2019;21:413-26.
van Vliet D, van Dam E, van Rijn M, Derks TG, Venema-Liefaard G, Hitzert MM, et al. Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented? JIMD Rep 2015;18:117-24.
Hickey RD, Nicolas CT, Allen K, Mao S, Elgilani F, Glorioso J, et al. Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1. Cell Transplant 2019;28:79-88.
Kaiser RA, Nicolas CT, Allen KL, Chilton JA, Du Z, Hickey RD, et al. Hepatotoxicity and Toxicology of In Vivo Lentiviral Vector Administration in Healthy and Liver-Injury Mouse Models. Hum Gene Ther Clin Dev 2019;30:57-66.
Thompson WS, Mondal G, Vanlith CJ, Kaiser RA, Lillegard JB. The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism. Expert Opinion on Orphan Drugs 2020;8:245-56.
Yazici H, Er E, Canda E, Habif S, Ucar S, Coker M. Clinical Features of 29 Patients with Hereditary Tyrosinemia I in Western Turkey. The Journal of Pediatric Research 2018;5.
Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepatic medicine : evidence and research 2016;8:39-50.
Baumann M, Witzke O, Canbay A, Patschan S, Treichel U, Gerken G, et al. Serum C3 complement concentrations correlate with liver function in patients with liver cirrhosis. Hepatogastroenterology 2004;51:1451-3.
Ministry of Health and Welfare. Maternal and child health service 2020. 2020. p. 192.
Jun SH, Do Seo J, Lee K, Song J. Measurement of Succinylacetone Using HPLC-Tandem Mass Spectrometry and Establishment of a Cut-off Value. Journal of Laboratory Medicine and Quality Assurance 2018;40:149-54.
Metz TF, Mechtler TP, Merk M, Gottschalk A, Lukacin R, Herkner KR, et al. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine. Clinica Chimica Acta 2012;413:1259-64.
la Marca G, Malvagia S, Pasquini E, Cavicchi C, Morrone A, Ciani F, et al. Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential. JIMD Rep 2011;1:107-9.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.